Hormone Therapy,Dilemmas,Medical Decisions

van Keep P. A. , “The History And Rationale of Hormone Replacement Therapy,” Maturitas 12, no. 3 (1990): 163–170.

McEwen B. S. Akama K. Alves S. Brake W. G. Bulloch K. Lee S. , “Tracking the Estrogen Receptor in Neurons: Implications for Estrogen-Induced Synapse Formation,” Proceedings of the National Academy of Sciences 98, no. 13 (2001): 7093–7100.

Barrett-Connor E. , “Cardiovascular Endocrinology 3: An Epidemiologist Looks at Hormones And Heart Disease,” Journal of Clinical Endocrinology and Metabolism 88, no. 9 (2003): 4031–4042.

Haas J. S. Kaplan C. P. Gerstenberger E. P. Kerlokowsje K. , “Changes in the Use of Postmenopausal Hormone Therapy After the Publication on Clinical Trial Results,” Annals of Internal Medicine 140, no. 3 (2004): 184–188.

Watkins E. S. , “Dispensing with Aging: Changing Rationales for Long-Term Hormone Replacement Therapy 1960–2000,” Pharmacy in History 43, no. 1 (2001): 23–37.

Rossouw J. E. Finnegan L. P. Harlan W. R. Pinn V. W. Clifford C. McGowan J. A. , “The Evolution of the Women's Health Inititative: Perspectives from the NIH,” Journal of American Medical Women's Association 50 (1995): 50–55.

Wilson R. , Feminine Forever (New York: Evans, 1966).

Turgeon J. L. McDonnell D. P. Martin K. A. Wise P. M. , “Hormone Therapy: Physiological Complexity Belies Therapeutic Simplicity,” Science 304, no. 5675 (2004): 1269–1273.

Watkins E. S. , “Doctor, Are You Trying to Kill Me? Ambivalence about the Patient Package Insert for Estrogen,” Bulletin of Historical Medicine 76, no. 1 (2002): 84–104.

See van Keep , supra note 1.

Barrett-Connor E. , “Postmenopausal Estrogens – Current Prescribing Patterns of San Diego Gynecologists,” Western Journal of Medicine 144 (1986): 620–621.

Colditz G. A. , “The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women,” New England Journal of Medicine 332, no. 24 (1995): 1589–1593; Nelson H. D. Humphrey L. L. Nygren P. Teutsch S. M. Allan J. D. , “Postmenopausal Hormone Replacement Therapy: Scientific Review,” JAMA 288, no. 7 (2002): 872–881.

See Watkins , supra note 9.

Houck J. A. , Hot and Bothered: Women, Medicine and Menopause in Modern Medicine (Cambridge: Harvard University Press, 2006): 58–103.

Smith D. C. Prentice R. Thompson D. J. Herrmann W. L. , “Association of Exogenous Estrogen and Endometrial Cancer,” New England Journal of Medicine 293, no. 23 (1975): 1164–1167.

Ziel H. Finkle W. D. , “Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens,” New England Journal of Medicine 293, no. 27 (1975): 1167–1170.

Holzman G. B. Ravitch M. M. Metheny W. Rothert M. L. Holmes M. Hoppe R. B. , “Physicians' Judgments about Estrogen Replacement Therapy for Menopausal Women,” Obstetrics & Gynecology 63, no. 3 (1984): 303–309.

Whitehead M. I. Townsend P. T. Pryse-Davies J. Path F. R. C. Ryder T. A. King R. J. B. , “Effects of Estrogens and Progestins on the Biochemistry and Morphology of the Postmenopausal Endometrium,” New England Journal of Medicine 305, no. 27 (1981): 1599–1605.

Hersh A. L. Stefanick M. L. Stafford R. S. , “National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Trends,” JAMA 291, no. 1 (2004): 47–53.

See Barrett-Connor , supra note 3.

See Watkins , supra note 9; Houck , supra note 14.

See Barrett-Connor , supra note 3; Watkins , supra note 5; Houck , supra note 14.

Lock M. , Encounters with Aging (Berkeley: University of California Press, 1993): At 236–247.

Murtagh M. J. Hepworth J. , “Feminist Ethics and Menopause: Autonomy and Decision Making in Primary Care,” Social Science and Medicine 56, no. 8 (2003): 1643–1652.

See Lock , supra note 23; Avis N. E. Kaufert P. A. Lock M. McKinlay S. M. Vass K. , “The Evolution of Menopausal Symptoms,” Clinical Endocrinology and Metabolism 7, no. 7 (1993): 17–31.

Rothert M. , “Women's Use of Information Regarding Hormone Replacement Therapy,” Research in Nursing and Health 13, no. 6 (1990): 355–366.

Power M. L. Schulkin J. , “A Study of Patients of Obstetrician-Gynecologists about Their Knowledge of and Attitudes Towards Hormone Therapy,” Journal of Reproductive Medicine 51, no. 7 (2006): 525–532.

Belisle S. Reid R. Mills C. , “Cancer,” Le Journal d'obstétrique et gynécologie du Canada 28 (2006): S87–S94.

Hankinson S. Colditz G. A. Manson J. E. Speizer F. E. , Healthy Women, Healthy Lives (New York: Simon and Schuster, 2001).

Stampfer M. J. Willet W. C. Colditz G. A. Rosner B. Speizer F. E. , “A Prospective Study of Postmenopausal Estrogen and Coronary Heart Disease,” New England Journal of Medicine 313, no. 17 (1985): 1044–1049.

Wilson P. W. Garrison R. J. Castilli W. P. , “Postmenopausal Estrogen Use, Cigarette Smoking and Cardiovascular Morbidity in Women over 50: The Framingham Study,” New England Journal of Medicine 313, no. 17 (1985): 1038–1043.

Rossouw J. E. , “Coronary Heart Disease in Menopausal Women: Implications of Primary and Secondary Prevention Trials in Hormones,” Maturitas 51, no. 1 (2005): 51–63.

See Hankinson , supra note 29.

“National Institutes of Health State of the Science Conference on Management of Menopause-Related Symptoms,” March 2005, available at <http://consensus.nih.gov/2005/2005MenopausalSymptomsS0S025html.htm> (last visited December 11, 2007) [hereinafter cited as NIH State of the Science]; “Canadian Consensus Conference on Menopause,” Le Journal d'obstétrique et gynécologie du Canada 28, Special Edition (February 2006) 28: S1–S112, available at <http://sogc.medical.org/guidelines/public/171E-CONS-February2006.pdf> (last visited December 11, 2007) [hereinafter cited as Canadian Consensus].

V. Beral, Million Women Study Collaborators, “Breast Cancer and Hormone-Replacement Therapy in the Million Women Study,” The Lancet 362, no. 9832 (2003): 419–427.

Vickers M. Meade T. Darbyshire J. , “Women's International Study of Long Duration Oestrogen,” Climacteric 5, no. 4 (2002): 317–325.

Holmberg L. Anderson H. , “HABITS (Hormonal Replacement Therapy after Breast Cancer: Is It safe?): A Randomized Comparison Trial Stopped,” The Lancet 363, no. 9407 (2004): 453–455.

Chlebowski R. T. Hendrix S. L. Langer R. D. Stefanick M. L. Gass M. Lane D. , “Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial,” JAMA 289, no. 24 (2003): 3243–353.

Anderson G. L. , “Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy,” JAMA 291, no. 14 (2004): 1701–1711; Stefanick M. L. Anderson G. L. Margolis K. L. , “Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women with Hysterectomy,” JAMA 295, no. 14 (2006): 1647–1657.

See Belisle Reid Mills , supra note 28.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Armstrong K. Schwartz J. S. Randall T. Rubin S. C. Weber B. , “Hormone Replacement Therapy and Life Expectancy after Prophylactic Oophorectomy in Women with BRCA1/2 Mutations: A Decision Analysis,” Journal of Clinical Oncology 22, no. 6 (2004): 1045–1054.

See Canadian Consensus, supra note 34; Belisle , supra note 28.

Kahneman D. Tversky A. , “Prospect Theory: An Analysis of Decisions under Risk,” Econometrica 47, no. 2 (1979): 263–291.

See Holzman , supra note 17.

Grodstein F. , “Postmenopausal Hormone Therapy and Mortality,” New England Journal of Medicine 336, no. 25 (1997): 1769–1775.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Hodis H. N. Mack W. J. Azen S. P. Lobo R. A. Shoupe D. Mahrer P. R. , “Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women,” New England Journal of Medicine 349, no. 6 (2003): 535–545.

Manson J. E. Hsia J. Johnson K. C. Rossouw J. E. Assaf A. R. Lasser N. L. , “Estrogen Plus Progestin and the Risk of Coronary Heart Disease,” New England Journal of Medicine 349, no. 6 (2003): 523–534.

Lobo R. A. , “Appropriate Use of Hormones Should Alleviate Concerns of Cardiovascular and Breast Cancer Risk,” Maturitas 51, no. 1 (2005): 98–109.

Rossouw J. E. Anderson G. L. Prentice R. L. LaCroix A. Z. Kooperberg C. Stefanick M. L. , “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial,” JAMA 288, no. 3 (2002): 321–333.

Mastroianni A. C. Faden R. Federman D. , eds., Women and Health Research (Washington, D.C.: National Academy Press, 1994): At 1–18.

See Anderson , supra note 39.

See Canadian Consensus, supra note 34.

See Lobo , supra note 50.

Hsia J. Langer R. D. Manson J. E. , “Conjugated Equine Estrogens and Coronary Heart Disease,” Archives of Internal Medicine, 166, no. 3 (2006): 1701–1712.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Harman S. M. Naftolin F. Brinton E. A. Judelson D. R. , “Is the Estrogen Controversy Over?” Annals of the New York Academy of Sciences 1052 (2005): 43–56.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

See Lobo , supra note 50.

Schmidt P. J. , “Depression, the Perimenopause and Estrogen Therapy,” Annals of The New York Academy of Sciences 1052 (2005): 27–40.

See Schmidt , supra note 62.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Hays J. Ockene J. K. Brunner R. L. Kotchen J. M. Manson J. E. Patterson R. E. , “Effects of Estrogen Plus Progestin on Health-Related Quality of Life,” New England Journal of Medicine 348, no. 19 (2003): 1839–1854.

Brunner R. L. , “Effects of Conjugated Equine Estrogen on Health-Related Quality of Life in Postmenopausal Women with Hysterectomy,” Archives of Internal Medicine 165, no. 17 (2005): 1976–1986.

See Schmidt , supra note 62.

Grigoriadis S. Sherwin B. , “Mood and Memory” Le Journal d'obstétrique et gynécologie du Canada, special edition 1 (2006): S53–S59.

Yaffe K. , “Hormone Therapy and the Brain: Déjà Vu All Over Again?” JAMA 289, no. 20 (2003): 2717–2719.

Sherwin B. , “Surgical Menopause, Estrogen, and Cognitive Function in Women: What Do the Findings Tell Us?” New York Academy of Sciences 1052 (2005): 3–10.

Rapp S. R. Espeland M. A. Shumaker S. A. Henderson V. W. Brunner R. L. Manson J. E. , “Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women. Women's Health Initiative Memory Study: A Randomized Controlled Trial,” JAMA 289, no. 20 (2003): 2663–2672.

Espeland M. A. Rapp S. R. Shumaker S. A. Brunner R. Manson J. E. Sherwin B. B. , “Conjugated Equine Estrogens and Global Cognitive Function in Postmenopausal Women,” JAMA 291, no. 291 (2004): 2959–2968.

See Canadian Consensus, supra note 34.

Henderson V. W. , “Only a Matter of Time: Hormone Therapy and Cognition,” Menopause 12, no. 1 (2005): 1–3.

Bagger Y. Z. Tanko L. B. Alexanderson P. Qin G. Christiansen C. , “Early Postmenopausal Hormone Therapy May Prevent Impairment Later in Life,” Journal of the North American Menopause Society 12, no. 1 (2004): 12–17.

See Grigoriadis Sherwin , supra note 70.

See Bagger , supra note 77.

Shumaker S. A. Legault C. Rapp S. R. Thai L. Wallace R. B. Ockene J. K. , “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. Women's Health Initiative Memory Study: A Randomized Controlled Trial,” JAMA 289, no. 20 (2003): 2651–2662.

See Espeland , supra note 74.

Shumaker S. A. Legault C. Rapp S. R. Thai L. Lane D. S. , “Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women: Women's Health Initiative Memory Study,” JAMA 291, no. 24 (2004): 2947–2958.

Institute of Medicine, Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Flouride? (Washington, D.C.: National Academy of Sciences Press, 1997) [hereinafter cited as Institute of Medicine]; see NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Id. (Institute of Medicine and Canadian Consensus).

Greendale G. A. Espeland M. Slone S. Marcus R. Barrett-Connor E. , “Bone Mass Response to Discontinuation of Long-Term Hormone Replacement Therapy: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study,” Archives of Internal Medicine 162, no. 6 (2002): 665–672; see Institute of Medicine, supra note 83; Canadian Consensus, supra note 34.

Cauley J. A. Robbins J. Chen Z. Cumings S. R. Jackson R. D. LaCroix A. Z. , “Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial,” JAMA 290, no. 13 (2003): 1729–1738.

See Cauley , supra note 86; Anderson , supra note 39; NIH State of the Science, supra note 34.

See NIH State of the Science, supra note 34; Canadian Consensus, supra note 34.

Banks E. Beral V. Reeves G. Balkwill A. Barnes I. , “Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women,” JAMA 291, no. 18 (2004): 2212–2220.

See Institute of Medicine, supra note 83; Canadian Consensus, supra note 34.

Id. (Canadian Consensus).

See Hersh , supra note 19.

See Watkins , supra note 5; Houck , supra note 12.

Katz A. , “Observations and Advertising: Controversies in the Prescribing of Hormone Replacement Therapy,” Health Care for Women International 24, no. 10 (2003): 927–939.

See Watkins , supra note 9.

Whittaker R. , “Reframing The Representation of Women in Advertisements for Hormone Replacement Therapy,” Nursing Inquiry 5, no. 2 (1998): 77–86.

Telephone conversation between author and Kate Mertes of Mertes Editorial Services, August 2006.

See Katz , supra note 94; Whittaker , supra note 96.

See Watkins , supra note 5; Watkins , supra note 9.

Id. (2001).

Morgan M. A. Dana J. Loewenstein G. Zinberg S. Schulkin J. , “Interactions of Doctors with the Pharmaceutical Industry,” Journal of Medical Ethics 32 (2006): 559–563; Chew L. D. O'Young T. S. Hazlet T. K. Bradley K. A. Maynard C. Lessler D. S. , “A Physician Survey on the Effect of Drug Sample Availability on Physicians' Behavior,” Journal of General Internal Medicine 15, no. 7 (2000): 478–483.

See Katz , supra note 94.

Dana J. Loewenstein G. , “A Social Science Perspective on Gifts to Physicians from Industry,” JAMA 290, no. 2 (2003): 252–255.

See Morgan , supra note 101.

See Dana Loewenstein , supra note 103.

Morgan M. A. Schulkin J. , “Obstetrician Gynecologists and Self-Identified Depression: Personal and Clinical,” Depression and Anxiety 23, no. 2 (2006): 83–89.

See Morgan , supra note 101.

American College of Obstetricians and Gynecologists, “Guidelines for Relationships with Industry,” in Ethics in Obstetrics and Gynecology, Washington, D.C., 2002: At 40–43 [hereinafter cited as ACOG Guidelines].

American Medical Association, Opinion of the Council on Ethical and Judicial Affairs , 2005, available at <www.ama-assn.org/ama/pub/category/4325.html>; see id.

Angell M. , The Truth about the Drug Companies (New York: Random House, 2004): At 1–319.

See Morgan , supra note 101.

Warner R. , Morality in Medicine (Sherman Oaks, CA: Alfred Publishing Company, 1980): At 1–70.

Macklin R. , Enemies of Patients (Oxford: Oxford University Press, 1993): At 17–44.

Wolf S. M. , Feminism and Bioethics (Oxford: Oxford University Press, 1996): At 3–46.

Macklin R. , Against Relativism (Oxford: Oxford University Press, 1999): 89–109; Lyerly A. D. Myers E. R. Faden R. R. , “The Ethics of Aggregation and Hormone Replacement Therapy,” Health Care Analysis 9, no. 2 (2001): 187–211.

Sarokin D. Schulkin J. , “Environmentalism and the Right to Know: Expanding the Practice of Democracy,” Ecological Economics 4, no. 3 (1991): 175–189.

Dewey J. , Liberalism and Social Action (New York: Capricorn Books, 1935/1963): 1–92; Moreno J. D. , Deciding Together: Bioethics and Moral Consensus (Oxford: Oxford University Press, 1995): 106–125; Schulkin J. , Medical Decisions, Estrogen and Aging (New York: Springer Books, 2008).

Faden R. R. Beauchamp T. L. , “Decision Making and Informed Consent: A Study of the Impact of Disclosed Information,” Social Indicators Research 7, nos. 1–4 (1980): 313–336; see Wolf , supra note 114.

Pellegrino E. D. , “Patient Autonomy and the Physician's Ethics,” Annals of the Royal College of Physicians & Surgeons of Canada 27, no. 3 (1994): 171–173.

Veatch R. M. , “The Foundations of Bioethics,” Bioethics 13, (1999): 206–217.

Epstein R. M. Alper B. S. Quill T. F. , “Communicating Evidence for Participatory Decision Making,” JAMA 291, no. 19 (2004): 2359–2366.

Schneider A. E. Davis R. B. Phillips R. S. , “Discussion of Hormone Replacement Therapy between Physicians and Their Patients,” American Journal of Medical Quality 15, no. 14 (2000): 143–147.

Id. Power M. L. Zinberg S. Schulkin J. , “A Study of Obstetrician-Gynecologists Concerning Practice Patterns and Attitudes towards Hormone Therapy,” Menopause 13, no. 3 (2006): 434–441.

Legare F. O'Connor A. M. Graham I. D. Wells G. A. Jacobsen M. J. Elmsle T. Drake E. R. , “The Effect of Decision Aids on the Agreement between Women's and Physicians' Decisional Conflict about Hormone Replacement Therapy,” Patient Education and Counselling 50, no. 2 (2003): 211–221.

Ubel P. A. Jepson C. Baron J. , “The Inclusion of Patient Testimonials in Decision Aids: Effects of Treatment Choices,” Medical Decision Making 21, no. 1 (2001): 60–68.

Frankel H. L. Fitzpatrick M. K. Gaskell S. Hoff W. S. Rotondo M. F. Schwab C. W. , “Strategies to Improve Compliance with Evidence-Based Clinical Management Guidelines,” Journal of the American College of Surgeons 189, no. 6 (1999): 533–538.

O'Connor A. M. Stacey D. Rovner D. , “Decision Aids for People Facing Health Treatment or Screening Decisions,” Cochrane Database of Systematic Reviews 2 (2001): CD001431.

See Lyerly , supra note 115.

Baron J. , Thinking and Deciding (Cambridge: Cambridge University Press, 1988/2003): At 256–350; Baron J. Holzman C. B. Schulkin J. , “Attitudes of Obstetricians and Gynecologists toward Hormone Replacement Therapy,” Medical Decision Making 18, no. 4 (1998): 406–411; Power M. Baron J. Schulkin J. , “Factors Associated with Obstetrician-Gynecologists' Responses to the Women's Health Initiative Trial of Combined Hormone Therapy,” Medical Decision Making (in press, 2008); see Schulkin , supra note 117.

See Holzman , supra note 17.

Peterson H. B. Thacker S. B. Corso P. S. Marchbanks P. A. Koplan J. P. , “Hormone Therapy: Making Decisions in the Face of Uncertainty,” Archives of Internal Medicine 164, no. 21 (2004): 2308–2311.

Armstrong K. Popik S. Guerra C. Ubel P. A. , “Beliefs about Breast Cancer Risk and Use of Postmenopausal Hormone Replacement Therapy,” Medical Decision Making 20, no. 3 (2000): 308–313.

Macklin R. , “Ethical Principles in the Conduct of Research,” Experimental Gerontology 29, nos. 3–4 (1994): 519–524; see Lyerly , supra note 115.

See Katz , supra note 94.

Hendrix S. , “Menopausal Hormone Therapy Informed Consent,” American Journal of Obstetrics and Gynecology 189, no. 4, Supplement (2003): S31–S36.

Wilkes H. C. Meade T. W. , “Hormone Replacement Therapy in General Practice: A Survey of Doctors in the MRC's General Practice Research Framework,” BMJ 302, no. 6788 (1991): 1317–1320.

Schonberg M. A. Davis R. B. Wee C. C. , “After the WHI: Decision Making and Trust of Women Taking HT,” Women's Health Issues 15, no. 4 (2005): 187–195.

McCrea F. B. , “The Politics of Menopause: The Discovery of a Deficiency Disease,” Social Problems 31, no. 1 (1983): 111–123.

See Houck , supra note 14; Watkins , supra note 5; Watkins , supra note 9.

Krieger N. , “Hormone Replacement Therapy, Cancer, Controversies and Women's Health: Historical, Epidemiological, Biological, Clinical and Advocacy Perspectives,” Journal of Epidemiology and Community Health 59, no. 9 (2006): 740–748.

See Watkins , supra note 9; Katz , supra note 94.

Hess R. Chang C. Conigliaro J. McNeil M. , “Understanding Physicians' Attitudes towards Hormone Therapy,” Women's Health Issues 15, no. 1 (2005): 31–38.

Boodman S. , “Hormones Weather ‘The Change,’” Washington Post, September 20, 2005, at F1.

Cox D. , “Should a Doctor Prescribe Hormone Replacement Therapy Which Has Been Manufactured from Mare's Urine?” Journal of Medical Ethics 22, no. 4 (1996): 199–203.

Dewey J. , Theory of Valuation (Chicago: University of Chicago Press, 1939/1972): 1–66; see Moreno , supra note 117.

Caplan A. L. , “The Unnaturalness of Aging,” in Caplan A. L. McCartney J. J. Sisti D. A. , eds., Health, Disease and Illness (Washington, D.C.: Georgetown University Press, 2004): At 117–127.

Callahan D. , What Price Better Health (Berkeley: University of California Press, 2003); see id.

See Lock , supra note 23; id. (Caplan).